On September 9, the 5th Hong Kong International Biotechnology Forum and Exhibition (BIOHK2026) grandly opened at the Hong Kong Convention and Exhibition Centre. As a premier biotechnology industry event in Asia with global influence, the conference brought together leading biopharmaceutical enterprises, research institutions, industry experts and industrial capital from around the world. Focusing on cutting-edge technological innovation, cross-border industrial collaboration and medical ecosystem co-construction, it built a high-end international platform integrating academic exchange, technology transfer, international cooperation and resource matching, helping Asia's biotechnology industry connect with the world, innovate and upgrade, and achieve win-win development.

With strong support from governments at all levels and the strategic empowerment of the China-Singapore Guangzhou Knowledge City, Guangzhou Royal Lee Cancer Hospital, as a core international medical representative institution in the China-Singapore Guangzhou Knowledge City, was invited to appear at this top international industry event. It deeply participated in frontier dialogues on global biomedicine and cross-border healthcare, comprehensively showcasing the achievements of internationalization in high-end oncology care in the Greater Bay Area and its practical experience in cross-border services, demonstrating the strength of a regional international medical benchmark.YEO KIM SECK, CEO of Guangzhou Royal Lee Cancer Hospital, and Ma Lanying, Executive President for Medical Affairs and Head of International Medical Services, were invited to attend the conference.

During the event, the conference held a high-profile closed-door special promotion meeting on Guangzhou's biopharmaceutical industry, focusing on the internationalization layout of Guangzhou's biopharmaceutical industry and the innovative development of cross-border healthcare. At the meeting, Ma Lanying, Executive President for Medical Affairs of Guangzhou Royal Lee Cancer Hospital, delivered a keynote speech titled "Rooted in Huangpu China-Singapore Guangzhou Knowledge City: Building a New International Medical Hub." She systematically presented the hospital's international development layout, distinctive service system, and cross-border diagnosis and treatment practices to global industry guests, partners, and authoritative institutions.

The speech provided an in-depth analysis of the hospital's core strengths in high-end international services: upholding an inclusive international medical service philosophy, building a comprehensive international service system, creating multilingual culturally tailored rooms, and launching multilingual official platforms and 24-hour native-language one-on-one consultation services to meet the medical needs of patients from different countries, ethnicities, and cultures. Relying on a mature multidisciplinary oncology diagnosis and treatment system, the hospital has built full-life-cycle health management services for oncology chronic diseases. It has also innovatively created a full-process closed-loop cross-border service model of "overseas remote consultation — cross-border referral — cabin-to-hospital-door," thoroughly breaking down barriers for overseas patients seeking medical care in China. At the same time, the hospital has established a commercial insurance direct billing network covering more than 40 insurance companies worldwide, implemented long-term diagnosis and treatment cost optimization solutions, served patients from multiple countries, established 25+ authoritative medical strategic partnerships at home and abroad, deeply cultivated the "Belt and Road" medical and health cooperation landscape, and continuously built a global oncology diagnosis and treatment ecosystem. Its professional strength and international service model won high recognition and wide acclaim from all guests present.

On the afternoon of September 10, the conference's core parallel forum "Building a Cross-Border Medical Service Chain—Hong Kong as a Hub" grandly opened, focusing on core industry topics such as Guangzhou-Hong Kong linkage, Greater Bay Area synergy, and refined operation of cross-border healthcare in Southeast Asia. YEO KIM SECK, CEO of Guangzhou Royal Lee Cancer Hospital, was invited to attend the roundtable dialogue and explore new trends in cross-border healthcare development with global industry leaders.

 In his sharing, YEO KIM SECK deeply analyzed the refined operation system for cross-border oncology patients in the Greater Bay Area and Southeast Asia, detailed practical experience in using cross-border remote MDT with overseas experts and international second opinions to enhance patient trust and optimize clinical treatment outcomes, and from an industry perspective, analyzed the core competitiveness and long-term development logic of mainland high-end private oncology specialty hospitals deeply cultivating the cross-border healthcare track. He provided practical reference for the standardized, internationalized and scaled development of the cross-border healthcare industry in the Greater Bay Area. His unique insights and rich content received enthusiastic responses on site.

From a national strategic perspective, China's healthcare industry is accelerating its internationalization. Domestic high-end medical technology, diagnosis and treatment services, and scientific research translation capabilities are steadily ranking among the global first tier. China's international credibility, industry recognition and global influence in healthcare have risen significantly. Cross-border medical cooperation, international diagnosis and treatment services, and global collaboration in pharmaceutical technology have become new industry trends. Empowered by the dual national strategies of the Guangdong-Hong Kong-Macao Greater Bay Area and the Belt and Road Initiative, China's biopharmaceutical and high-end healthcare industries are ushering in a golden period of international development opportunities.

As a core carrier of the biopharmaceutical industry in the Greater Bay Area, the China-Singapore Guangzhou Knowledge City enjoys unique geographical, policy and industrial advantages. The region has deeply cultivated the entire biopharmaceutical industry chain, building a complete innovation system from basic research, technological breakthroughs, clinical translation to industrial implementation, and achieving an industrial pattern of deep synergy among "medicine, pharmaceuticals, devices, insurance and wellness." It provides a comprehensive industrial ecosystem and implementation ground for cross-border referrals, international commercial insurance matching, overseas medical technology implementation and clinical translation of innovative drugs. At the same time, relying on a high-standard GCP clinical translation platform, the region accelerates the compliant implementation and globally synchronized R&D of cutting-edge technologies such as gene therapy and innovative anti-cancer drugs. It links with leading domestic tertiary hospitals and top international medical systems such as Singapore to build a cross-border collaboration network for difficult and complex cases. It is a core hub for the Guangdong-Hong Kong-Macao Greater Bay Area to connect with global medical resources, receive international patients and implement high-end medical cooperation.

Guangzhou Royal Lee Cancer Hospital is deeply rooted in the core location of the China-Singapore Guangzhou Knowledge City. It is a key China-Singapore cooperation international medical benchmark project in the region, and also a core window and main carrier for the Knowledge City to receive global patients, carry out international medical cooperation and showcase the Greater Bay Area's high-end medical strength. Located in the Knowledge City, the hospital fully leverages the region's full-chain pharmaceutical industry ecosystem, global resource layout and strategic policy dividends to achieve two-way empowerment and coordinated development of medical services and industrial resources, laying a solid foundation for international diagnosis and treatment services, cross-border medical innovation, and integrated development of medicine, industry and services.

As a regional exclusive high-end international oncology specialty hospital, Royal Lee has always been based on a global vision, deeply cultivated locally, and empowered the development of international healthcare in the Greater Bay Area. Compared with similar institutions in the industry, the hospital has distinctive core advantages of internationalization, specialization and systematization: a mature global patient service system, a standardized cross-border diagnosis and treatment closed loop, a diversified international cooperation network and a top multidisciplinary diagnosis and treatment team. It combines the refined service and flexible operation of a high-end private hospital with the professional diagnosis and treatment strength of a public hospital. Relying on a comprehensive cross-border commercial insurance system, global expert collaboration resources and full-process international patient service capabilities, it continuously addresses the pain points of cross-border medical care and creates a high-end oncology diagnosis and treatment service model suitable for global patients.

The appearance at BIOHK2026, a top international event, is a powerful testament to Royal Lee's international development strength, and an important measure for the hospital to deeply integrate into the global medical industry landscape and help upgrade the internationalization of healthcare in the Greater Bay Area. In the future, Guangzhou Royal Lee Cancer Hospital will continue to be based on the strategic positioning of the China-Singapore Guangzhou Knowledge City, help build an integrated ecological closed loop of "medicine, pharmaceuticals, industry and services," continuously deepen global medical cooperation, refine high-end international diagnosis and treatment services, accelerate the translation and implementation of cutting-edge medical technologies, and strive to build a world-class oncology diagnosis and treatment center, promoting "For cancer care, come to Guangzhou" as a new international consensus, and striving to become the preferred destination for global oncology patients, helping China's high-end oncology medical care go global and empowering the development of global health.